Gradalis is a leading biotechnology company based in Carrollton, TX, specializing in the development of personalized cancer immunotherapy. With a focus on solid tumor types, including ovarian cancer, Gradalis is at the forefront of pioneering treatments with their innovative Vigil platform.
Through their unique process, Vigil offers fully personalized, patient-specific immunotherapy, providing a new way to fight cancer. With a dedicated scientific advisory board and a commitment to groundbreaking research, Gradalis is dedicated to improving the lives of cancer patients through their cutting-edge advancements in the field.
Generated from the website